Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker phenotype BEFREE Patients who achieved stable disease (SD) or progressive disease (PD) received EC (epirubicin and cyclophosphamide) or HT (trastuzumab and paclitaxel) according to their HER2 status.The primary end point was the pCR rate. 30340871 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker phenotype BEFREE When radiologic assessments documented progressive disease in target lesions, response to HER2 blockade was retained in other metastases. 29990497 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker phenotype BEFREE Exome analysis of patients with progressive disease (PD) revealed 1 CRC with high-level microsatellite instability and 1 instance of HER2 oncogene amplification; 3 of 4 remaining patients with PD had allergic reactions to cetuximab, while none of the subjects with PR or SD had this complication. 29470838 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker phenotype BEFREE Patients with advanced or recurrent HER2-positive gastric adenocarcinoma who were diagnosed with progressive disease after the first-line trastuzumab-based therapy and developed pathologically confirmed adenocarcinoma within 3 months after completion of trastuzumab-based therapy were enrolled in this study. 30391779 2018
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker phenotype BEFREE In this Phase I/II study, we evaluated the toxicity and response rate after treatment with SAHA and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with trastuzumab-resistant progressive disease. 28623430 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker phenotype BEFREE In Her-2-positive metastatic breast cancers, PTEN positivity was significantly associated with progressive disease, but not with PFS or OS. 28253285 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker phenotype BEFREE A female patient with oestrogen receptor-positive and human epidermal growth factor receptor 2 (HER2)-positive invasive lobular breast cancer presented with progressive disease on CT scan. 28687693 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 GeneticVariation phenotype BEFREE Of 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease). 27105424 2016
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression phenotype BEFREE A total of 52 patients were evaluable.H2T level was significantly higher in responders (median 93.49 in partial response, 47.66 in stable disease, and 17.27 in progressive disease; p = 0.020). 22848366 2012
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker phenotype BEFREE Current HER2-directed therapies confer limited clinical benefits and most patients experience progressive disease. 20179231 2010
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker phenotype BEFREE Multivariate analysis demonstrated that anthracycline plus taxane chemotherapy (P = 0.006), NG3 (P = 0.006), HR-negativity (P = 0.013), and HER2-positivity (P = 0.010) were significant predictors of pCR, and T3-4 (P = 0.002) and NG3 (P = 0.010) were significant predictors of PD. 20143238 2010
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 AlteredExpression phenotype BEFREE Her2 (ErbB2) protein is overexpressed in breast and other solid tumors, and its expression is associated with progressive disease. 19347621 2009
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker phenotype BEFREE No association was found between HER-2 gene amplification and response to anthracyclines (5/14 (36%) CR and 5/17 (29%) PD to anthracycline-based CT were HER-2+). 14654958 2004